Ortho Clinical Diagnostics Opens Manufacturing Facility In Wales
Plant to manufacture immunodiagnostic tests to help early detection of diseases
Ortho Clinical Diagnostics (OCD) has opened a new manufacturing facility in Pencoed, Wales. The new, 110,000 square feet facility would employ over 350 people in manufacturing operations, quality, product technical support, human resources, finance, and information technology.
The plant would manufacture immunodiagnostic tests that can help detect diseases early, leading to patient care and treatment that is likely to helpavoid progression to more serious disease. Immunodiagnostic tests indicate the presence or level of a protein to help diagnose disease in categories such as thyroid function, reproductive endocrinology, cardiology, anemia, metabolism, oncology and infectious diseases.
John Gethin, General Manager, Ortho Clinical Diagnostics, said: OCD has almost 30 years of manufacturing history in Wales and continues to invest in the region with the opening of the Pencoed facility. The opening of this new facility enables OCD to provide our customers worldwide with advances in diagnostics to improve patient care.
Related Insight
Suppliers Directory
GxPi - Consulting and Compliant Document Management Solutions
GxPi specialises in simple to use Quality & Lean Compliance solutions for the Life Science industry. Specifically looking after the smaller companies in the sector. Either through x-docs™ (our Microsoft SharePoint based content/document management solution) or high value, high impact consulting services.
Suppliers
Genetic Analysis - Molecular Diagnostics of Diseases Related to Gut Imbalances
Genetic Analysis AS (GA) offers a DNA based comprehensive gut bacteria analysis and has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances.
Suppliers
Axiom Real Time Metrics - EDC Solutions
As experts in EDC products and implementation, we help simplify the potential challenges of using EDC. We assist with technology, personnel and process.
Suppliers
Treff - Custom Moulded Plastic Parts
Treff, a leading Swiss manufacturer of plastic consumables and plastic medical components for the diagnostic and medical sector, has made a name for itself as an OEM-partner of important manufacturers of diagnostic and medical devices and life science robotics.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Contamination Concerns
Published by Phage Consultants
White Papers
The SensaSlim Solution
Published by SensaSlim
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.